Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00924196 | Natural History Study of Patients With Neurofibromatosis Type I | active not recruiting | — | 259 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 |
| clinicaltrials |
| NCT03971461 | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | active not recruiting | Phase 2 | 32 | NYU Langone HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04085887 | Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures | recruiting | Phase 1 / Phase 2 | 12 | Stanford UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04724369 | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma | completed | Phase 3 | 43 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05871021 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma(PRIDE) | active not recruiting | Phase 2 | 107 | University Hospital TuebingenOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT06325683 | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | suspended | Phase 2 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07219199 | Residual IDH1-Mutant Tumor Cell Quantification Study | not yet recruiting | N/A | 105 | NYU Langone HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07374692 | Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors | completed | — | 4 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07488780 | Language Network Prehab Via fMRI Neurofeedback | recruiting | N/A | 4 | Yale UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07492316 | RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)(PNOC020 rMB) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845994 | SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years(SEMAFORCRANIO) | not yet recruiting | Phase 3 | 50 | University Hospital, AngersOTHER_GOV | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00314119 | Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | completed | — | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01109394 | Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies | recruiting | — | 6,035 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01362803 | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | active not recruiting | Phase 1 / Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | active not recruiting | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05303467 | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM(FRONTIER) | recruiting | Phase 1 | 36 | Boston Scientific CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05432804 | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | recruiting | Phase 1 / Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07145112 | Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma | recruiting | Phase 1 | 25 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | recruiting | Phase 2 | 162 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07346157 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) | recruiting | Phase 1 / Phase 2 | 69 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07839247 | Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL | recruiting | Phase 2 | 33 | Xiaohui RenOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844460 | 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features | enrolling by invitation | — | 30 | Shengjing HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02015117 | Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | active not recruiting | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02389309 | Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors | active not recruiting | Phase 1 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03896568 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03969706 | Abemaciclib in Patients With Oligodendroglioma | completed | Phase 2 | 10 | Stephen Bagley, MD, MSCEOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05099003 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 4 | Sep 25, 2026 | clinicaltrials |
| NCT05183204 | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | completed | Phase 2 | 24 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06441331 | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors(KinLET) | recruiting | Phase 1 | 20 | ITM Solucin GmbHINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07195591 | Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care(BRIDGES) | recruiting | Phase 3 | 766 | GT Medical Technologies, Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07224503 | C-SMART vs BE Well for Patients With Brain Tumors | recruiting | N/A | 56 | Virginia Commonwealth UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07422896 | A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma(Bvax) | not yet recruiting | Phase 1 | 25 | Catalina Lee ChangOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842835 | Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB)(CLIMB) | not yet recruiting | — | 400 | Xiaohui RenOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT01944761 | The Neuro-protective Effects of Exercise in Children With Brain Tumors | completed | N/A | 32 | The Hospital for Sick ChildrenOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02040376 | Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma | completed | Phase 3 | 24 | The Hospital for Sick ChildrenOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02573441 | KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer | completed | N/A | 28 | The Hospital for Sick ChildrenOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03893110 | Carbon PEEK Versus Titanium Pedicle Screws in the Treatment of Spinal Tumors | withdrawn | N/A | 0 | Balgrist University HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04115761 | Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients | recruiting | Phase 2 | 24 | Ever Supreme Bio Technology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04868799 | Finding New Targets by Proteomic Approaches (InnovRT1)(InnovRT1) | completed | — | 44 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05230758 | Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour(Met Med Can) | recruiting | Phase 3 | 140 | Donald MabbottOTHER | 2 | Sep 24, 2026 | clinicaltrials |
| NCT05367076 | Fitness to Aid the Brain and Cognitive Skills(Fit ABCS) | completed | N/A | 26 | The Hospital for Sick ChildrenOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05635734 | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Cantex PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials